Please use this identifier to cite or link to this item:
|Title:||Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis||Authors:||Abi Chahine, Nassim
|Affiliations:||Faculty of Arts and Sciences||Keywords:||Autologous bone marrow
The expanded disability status scale
|Issue Date:||2016-11-30||Publisher:||National Library of Medicine||Part of:||International Journal of Stem Cells||Volume:||9||Issue:||2||Start page:||207||End page:||212||Abstract:||
Stem cell therapy, an evolving, progressive field of therapeutics has shown several successes in areas where classic treatments failed to prevent or stop disability. Starting in 2009, twenty two sequential patients with progressive Multiple Sclerosis (MS) courses were treated with Autologous Bone Marrow Mononuclear stem cells (BM-MNSCs). The cells were given both intravenously and intrathecally. Using the Expanded Disability Status Scale (EDSS) score for evaluation, our data indicates that the majority of the patients benefited on the average one point on the scale. This paper adds to the body of evidence suggesting the safety and efficacy of autologous BM-MNSCs in the treatment of MS and awaits validation through larger, randomized studies.
|URI:||https://scholarhub.balamand.edu.lb/handle/uob/5958||ISSN:||2005-3606||DOI:||10.15283/ijsc16049||Open URL:||Link to full text||Type:||Journal Article|
|Appears in Collections:||Department of Biology|
Show full item record
checked on Dec 3, 2022
checked on Dec 6, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.